Hasil Pencarian  ::  Simpan CSV :: Kembali

"Transformasi Virus SARS-CoV-2 menghasilkan evolusi virus. Pemahaman mekanisme COVID-19 membantu stratifikasi risiko dan memperkuat manajemen COVID-19. Peningkatan 16 hingga 53% enzim hepar pada pasien dengan infeksi SARS-COV-2 diperlukan telaah terkait dengan SGOT, SGPT dan rasio De ritis. Rangkaian respon inflamasi pada infeksi COVID-19 melibatkan interleukin-6 (IL-6), C-reactive protein (CRP) dan albumin berkorelasi langsung dengan derajat peradangan. Rasio CRP terhadap albumin merupakan indikator baru status inflamasi yang lebih andal dibandingkan CRP atau albumin saja. Luaran buruk pada penelitian jika selama perawatan terdapat perawatan di ruang intensif, penggunaan ventilator mekanik dan atau kematian. Penelitian ini mencoba menganalisis parameter fungsi hepar dan inflamasi pada 48 jam awal perawatan dalam memprediksi luaran buruk pasien dengan COVID-19. Sejumlah 66 data pasien yang terdiri dari 16 data luaran buruk diikutsertakan pada penelitian. Median SGOT,IL-6, CRP, albumin, dan rasio CRP/albumin bermakna dibandingkan kelompok luaran tidak buruk. Titik potong optimal IL-6, CRP dan Rasio CRP/Albumin dalam menentukan luaran buruk sebesar 60,03 pg/ml, 32,5 mg/L dan 10,5. Model prediksi luaran buruk COVID-19 disusun dari parameter komorbid hipertensi, diabetes dan rasio CRP/Albumin

---

Transformation SARS-CoV-2 virus resulted in the evolution of the virus. Understanding mechanisms of COVID-19 contributed for risk stratification and strengthening the management COVID-19. Elevated liver enzymes 16 to 53% in patients with SARS-COV-2 infection requires more concern especially SGOT, SGPT and De ritis ratio. The series of inflammatory responses in COVID-19 infection involving interleukin-6 (IL-6), C-reactive protein (CRP) and albumin directly correlates with the degree of inflammation. CRP to albumin ratio is a new indicator of inflammatory status that more reliable than CRP or albumin alone. Poor outcome stated if during treatment there was intensive care unit treatment, use of a mechanical ventilator and/or death. This study tries to analyze whether liver function and inflammation parameters in the initial 48 hours of treatment can be used to predict poor outcomes in patients with COVID-19. A total of 66 patient data consisting of 16 poor outcome data were included in the study. Median SGOT, IL-6, CRP, albumin, and CRP/albumin ratio were significant compared to the non-poor outcome group. The optimal cut points for IL-6, CRP and CRP/Albumin ratio in determining poor outcomes are 60.03 pg/ml, 32.5 mg/L and 10.5. The prediction model for poor outcomes for COVID-19 is compiled from the comorbid parameters of hypertension, diabetes and CRP/Albumin ratio"

"Latar Belakang: Saat ini hubungan antara kejadian SVR12 pasien hepatitis C, profil lipid, dan steatosis hati masih belum jelas. Hasil publikasi yang ada saat ini masih tidak konsisten mengenai perubahan nilai parameter tersebut pasca SVR12. Di Indonesia sendiri, belum ada penelitian yang mengevaluasi kejadian steatosis hati pasca SVR12, padahal karakteristik populasi di Indonesia berbeda dengan populasi negara lain. Penelitian ini bertujuan untuk meneliti perubahan derajat steatosis hati dan profil lipid pada pasien hepatitis C saat SVR12 dan mencari hubungannya.Metode: Penelitian dengan desain longitudinal, before and after study yang dilakukan di Rumah Sakit Cipto Mangunkusumo (RSCM). Penelitian dilakukan selama 1 tahun di Poliklinik Hepatobilier, Ruang Prosedur Terpadu (RPT) Divisi Hepatobilier. Pasien yang memenuhi kriteria inklusi akan diikutsertakan dan diperiksa profil lipid dan nilai controlled attenuated parameter sebelum dan sesudah terapi.Hasil: Rerata SD sampel penelitian adalah 45±8.78 tahun. Subjek sebagian besar (62%) berjenis kelamin laki-laki. Nilai rerata SD CAP meningkat, sebelum terapi 196±49.36 dB/m dan setelah terapi 227±47.11 dB/m. Nilai rerata SD kolesterol total meningkat, sebelum terapi 166±40.30 mg/dL dan setelah terapi 190±42.58 mg/dL. Nilai rerata SD trigliserida, sebelum terapi 94±45.39 mg/dL dan setelah terapi 109±49.83 mg/dL. Nilai rerata SD HDL meningkat, sebelum terapi 44.4±15.02 mg/dL dan setelah terapi 47.0±17.20 mg/dL. Nilai rerata SD LDL meningkat, sebelum terapi 109.48±39.57 mg/dL dan setelah terapi 130.88±34.32 mg/dL. Tidak ditemukan korelasi korelasi delta berbagai jenis kolesterol dengan delta CAP. Ditemukan adanya korelasi negatif antara nilai CAP pada pasien hepatitis C sebelum terapi dan perubahan nilai CAP sesudah terapi DAA. Terdapat penurunan nilai rerata SD kekakuan hati, sebelum terapi 6.90±2.34 kPa dan setelah terapi 5.35±1.79 kPa. Terdapat penurunan nilai median APRI, sebelum terapi 0.50 (0.3 – 0.7) dan setelah terapi 0.20 (0.20 – 0.30).Simpulan: 1) Terdapat perbedaan derajat steatosis hati sebelum terapi dan saat SVR12 pada pasien hepatitis C yang mendapat terapi DAA. 2) Terdapat perbedaan kadar kolesterol total, kolesterol HDL, kolesterol LDL, dan trigliserida sebelum terapi dan saat SVR12 pada pasien hepatitis C yang mendapat terapi DAA. 3) Tidak terdapat korelasi perubahan kadar kolesterol total, kolesterol HDL, kolesterol LDL, dan trigliserida terhadap derajat steatosis hati saat SVR12.

---

Background: Currently, the relationship between hepatitis C patients' SVR12 events, lipid profiles and liver steatosis remains unclear. Current publications are inconsistent regarding the changes in these parameters after SVR12. In Indonesia alone, there are no studies evaluating the incidence of liver steatosis after SVR12, even though the characteristics of the population in Indonesia are different from those in other countries. This study aims to examine changes in the degree of hepatic steatosis and lipid profile in hepatitis C patients during SVR12 and find out the relationship.

Method: Longitudinal design, before and after study conducted at Cipto Mangunkusumo Hospital (RSCM). The study was conducted for 1 year at the Hepatobiliary Polyclinic, Integrated Procedure Room of the Hepatobiliary Division. Patients who met the inclusion criteria were included and examined for lipid profile and controlled attenuated parameter values before and after therapy.

Results: The mean age SD is 45±8.78 years. Subjects were mostly (62%) male. The mean SD value of CAP increased, before therapy 196±49.36 dB/m and after therapy 227±47.11 dB/m. The mean SD value of total cholesterol increased, before therapy 166±40.30 mg/dL and after therapy 190±42.58 mg/dL. The SD mean value of triglycerides, before therapy 94±45.39 mg/dL and after therapy 109±49.83 mg/dL. The mean SD value of HDL increased, before therapy 44.4±15.02 mg/dL and after therapy 47.0±17.20 mg/dL. The mean SD value of LDL increased, before therapy 109.48±39.57 mg/dL and after therapy 130.88±34.32 mg/dL. There was no correlation between the delta of various types of cholesterol and the delta of CAP. There was a negative correlation between CAP values in hepatitis C patients before therapy and changes in CAP values after DAA therapy. There was a decrease in the mean SD value of liver stiffness, before therapy 6.90±2.34 kPa and after therapy 5.35±1.79 kPa. There was a decrease in the median APRI value, before therapy 0.50 (0.3 - 0.7) and after therapy 0.20 (0.20 - 0.30).

Conclusion: 1) There is a difference in the degree of liver steatosis before therapy and after SVR12 in hepatitis C patients who received DAA therapy. 2) There are differences in total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride levels before therapy and after SVR12 in hepatitis C patients who received DAA therapy. 3) There is no effect of changes in total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides before therapy and after SVR12 on the degree of liver steatosis after SVR12."